HomeREGULATORY
REGULATORY

Opdivo Could Face Deeper Cut with Revision of Dosage-Change Re-Pricing Rule; Keytruda Could Be Affected Too
(Oct.30.2017)

The Ministry of Health, Labor and Welfare (MHLW) is eyeing a tweak to a dosage-related drug re-pricing rule, which would subject Ono Pharmaceutical’s PD-1 inhibitor Opdivo (nivolumab) to a 56% cut from its initial NHI price - or a price before a 50% special price slash in February this year - with MSD’s archrival in the class, Keytruda (pembrolizumab), also to be possibly affected. With debates on a series of other reform plans also ongoing, however, the final pricing of the immuno-oncology drug in April next year is still uncertain ...
(LOG IN FOR FULL STORY)

News Calendar